Cancer Immunity 13:5 (2013)
نویسندگان
چکیده
4387. 108.Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010; 37: 473-484. (PMID: 21074063) 109.Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFN-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008; 105: 14987-14992. (PMID: 18818309) 110.Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 2008; 6: 22. (PMID: 18452610) 111.Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9: 204. (PMID: 22123319) 112.Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 2011; 108: 16723-16728. (PMID: 21933959) 113.Petrausch U, Haley D, Miller W, Floyd K, Urba WJ, Walker E. Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data. Cytometry A 2006; 69: 1162-1173. (PMID: 17089357) Contact Address correspondence to: Joseph F. Grosso, Ph.D. Bristol-Myers Squibb Pharmaceutical Research Institute Route 206 and Province Line Road P.O. Box 4000 www.cancerimmunity.org 13 of 14 Cancer Immunity (22 January 2013) Vol. 13, p. 5 Princeton, NJ 08543 USA Tel.: + 1 609 252 4829 Fax: + 1 609 252 6816 E-mail: [email protected] 14 of 14 www.cancerimmunity.org
منابع مشابه
Immunoglobulin GM allotypes as effect modifiers of cytomegalovirus-spurred neuroblastoma.
An uncommon immunoglobulin GM (γ marker) genotype has been reported to be strongly associated with susceptibility to neuroblastoma, but the mechanism(s) underlying this association is not known. Increasing evidence implicates human cytomegalovirus (HCMV) in the pathogenesis of neuroblastoma. HCMV has evolved a large repertoire of sophisticated strategies to evade host immunosurveillance. Partic...
متن کاملCan immunity to breast cancer eliminate residual micrometastases?
An effective immune response has the potential for breast cancer sterilization with marked reduction in the potential for disease relapse. Adaptive type I immune cells uniquely have the capability of (i) cytotoxic T-cell activation and proliferation until all antigen expressing cells are eradicated, (ii) traversing endothelial barriers to penetrate tumor deposits wherever they occur, and (iii) ...
متن کاملGetting personal with neoantigen-based therapeutic cancer vaccines.
Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide hi...
متن کاملInnate immune cells in inflammation and cancer.
The innate immune system has evolved in multicellular organisms to detect and respond to situations that compromise tissue homeostasis. It comprises a set of tissue-resident and circulating leukocytes primarily designed to sense pathogens and tissue damage through hardwired receptors and eliminate noxious sources by mediating inflammatory processes. While indispensable to immunity, the inflamma...
متن کاملPlasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL.
Even though melanoma is considered to be one of the most immunogenic solid tumors, handling its development remains a challenge. The basis for such escape from antitumor immune control has not yet been documented. Plasmacytoid dendritic cells (pDC) are emerging as crucial but still enigmatic cells in cancer. In melanoma, the function of tumor-infiltrating pDCs remains poorly explored. We invest...
متن کاملCancer Immunity 13:6 (2013)
1Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA 2Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA 3Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA 4Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA *Present address: Eppley Institute for Research in Cancer, Universit...
متن کامل